Navigation Links
McNeil Consumer Healthcare Announces Voluntary Recall of One Product Lot of TYLENOL® 8 Hour Caplets 50 Count Sold in the United States and Puerto Rico
Date:10/18/2010

FORT WASHINGTON, Pa., Oct. 18 /PRNewswire/ -- McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is recalling one product lot of TYLENOL® 8 Hour caplets 50 count bottles to the retail level.  McNeil is taking this action following a small number of complaints of a musty or moldy odor.  The uncharacteristic odor is thought to be caused by the presence of trace amounts of a chemical called  2,4,6-tribromoanisole.  This voluntary action is being taken as a precaution and the risk of adverse medical events is remote.  To date, observed events reported to McNeil for this lot were temporary and non-serious.

The product lot number for the recalled product can be found on the side of the bottle label.

FULL RECALLED PRODUCT LIST:Product NameLot NumberUPC CodeTYLENOL® 8 HOUR CAPLET 50 count 

BCM155

3 0045-0297-51 8 Consumers who purchased product from the lot included in this recall should stop using the product and contact McNeil Consumer Healthcare, either at www.tylenol.com or by calling 1-888-222-6036 (Monday-Friday 8 a.m. to 8 p.m. Eastern Time, and Saturday-Sunday 9 a.m. to 5 p.m. Eastern Time) for instructions about receiving a refund or product coupon. Consumers who have medical concerns or questions should contact their healthcare provider.  

Any adverse reactions may also be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Online: www.fda.gov/medwatch/report.htm
  • Regular Mail: use postage-paid, pre-addressed Form FDA 3500 available at: www.fda.gov/MedWatch/getforms.htm. Mail to address on the pre-addressed form.
  • Fax: 1-800-FDA-0178

  • This recall is being conducted with the knowledge of the U.S. Food and Drug Admini
    '/>"/>

    SOURCE McNeil Consumer Healthcare
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT
    2. The Pittsburgh Life Sciences Greenhouse Congratulates Diamyd Medical on Its Agreement with Ortho-McNeil-Janssen Pharmaceuticals to Develop Diabetes Therapy
    3. Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million
    4. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities
    5. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Agrees to $75 Million Settlement for Topamax(R) False Claims Lawsuit
    6. McNeil Consumer Healthcare Announces a Voluntary Nationwide Recall of All Lots of TYLENOL(R) Arthritis Pain 100 Count With EZ-OPEN CAP
    7. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season
    8. McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP
    9. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
    10. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
    11. FDA Consumer Health Information - FDA Tightens Reins on Unapproved Chelation Drugs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
    (Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
    (Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
    Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
    ... MELBOURNE, Australia, Oct. 24, 2011 Key Points ... 2 trial for wet Age-related Macular Degeneration (AMD) ... Mesoblast,s allogeneic ("off-the-shelf") cells with anti-VEGF agent Wet AMD, ... forms in Asia and North America/Europe Anti-VEGF agents are ...
    ... today announced that it has received the Stroke Care ... placing it among the top 5 percent of hospitals ... mortality rates for stroke treatment and pulmonary services. ... with HealthGrades, Five-Star Rating and ranked as the number ...
    Cached Medicine Technology:Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 2Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 3Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 4Evergreen Named One of America's 100 Best Hospitals for Stroke Care 2Evergreen Named One of America's 100 Best Hospitals for Stroke Care 3
    (Date:4/17/2014)... has found that India,s shocking rates of suicide are ... are clinging to tiny smallholdings less than one ... as cotton and coffee, that are highly susceptible to ... of previous case studies that point to a crisis ... ,liberalisation, of the nation,s economy during the 90s. Researchers ...
    (Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
    (Date:4/17/2014)... that lost its status as the leading weapon against ... of life, with new research indicating it simply needs ... the use of the cheap anti-malarial drug chloroquine in ... lives of more than half a million people each ... malaria has developed resistance to chloroquine, but research carried ...
    (Date:4/16/2014)... , STANFORD, Calif. Consider the marvel of the embryo. ... shape and function as they multiply to become the cells ... tissues of the body. , Now, in a feat of ... the complex genetic coding that allows embryonic cells to proliferate ...
    (Date:4/16/2014)... 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today ... CDX-1401 in solid tumors, including long-term patient follow-up, have ... 6 Issue 232). The data demonstrate robust antibody and ... patients with very advanced cancers and suggest that CDX-1401 ...
    Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
    ... ... new book “A must have...The Maroema Cook Book” by Mamta Reid of Tokyo’s MAROEMA Vegetarian ... (PRWEB) May 6, ... new inspiration with the release of “A must have...The Maroema Cook Book” by Mamta Reid. ...
    ... heart disease and stroke rates in China will rise ... aging population and other increased risk factors, without policies ... smoking, according to research from Columbia University Medical Center ... an American Heart Association journal. "China,s standard of ...
    ... events , WEDNESDAY, May 5 (HealthDay News) -- A ... significantly cuts down on hospital drug errors, researchers from ... "We had the opportunity to design and implement a ... the hospital gets the right medication at the right ...
    ... Researchers at the University of Toronto have discovered a ... number of genes to generate enormously complex organs such as ... in the journal Nature entitled "Deciphering the Splicing ... Benjamin Blencowe of the University of Toronto describes how a ...
    ... Nausea in pregnant women tends to fade after the ... it can be a sign of flu, researchers at UT ... women who sought medical care. "People don,t necessarily think ... vomiting, but our study showed that they are common with ...
    ... finds , WEDNESDAY, May 5 (HealthDay News) -- People who,ve ... face an increased risk for heart complications and death if ... study has found. , "We looked at the risks connected ... Nicholas L.M. Cruden, a former cardiology lecturer at the University ...
    Cached Medicine News:Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 2Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 3Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 2Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 3Health News:Bar Codes Cut Down on Hospital Medication Errors 2Health News:Bar Codes Cut Down on Hospital Medication Errors 3Health News:U of T researchers crack 'splicing code,' solve a mystery underlying biological complexity 2Health News:Nausea and speeding heart can be signs of flu in pregnant women 2Health News:Risks Rise for Other Surgeries After Stent Implants 2
    ... Acid is a non-irritating rapid exfoliator. Lactic Acid ... to peel and exfoliating agents in skin care ... other exfoliators for a long period and want ... occurring human metabolite, and combined with the chemical ...
    ... is available in two innovative formulations: Level ... active). The Level I (40% active) formulation ... extract, which DCL scientists have identified and ... and calm the skin while the beneficial ...
    ... CosmoDerm and CosmoPlast are dermal fillers ... acne scars and other soft tissue contour ... of the lip border. The collagen in ... dermal tissue that is grown under controlled ...
    ... is a gel of ... species of bacteria, chemically ... suspended in phosphate,buffered saline ... and concentration of 20 ...
    Medicine Products: